Skip to content

4 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Sequencing-informed, patient-specific droplet digital PCR assays for circulating tumor DNA monitoring in recurrent or metastatic head and neck cancer: a pilot study

Background In recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC), early identification of treatment response remains challenging because imaging may be delayed or confounded by treatment-related changes and atypical response patterns under immunotherapy. Serial circulating tumor DNA (ctDNA) analy...

Luca Leonardo Amodio, Lea Grossmann, Stefanie Gächter et al. · 0 citations
Open access Oct 2026

Sequencing-informed, patient-specific droplet digital PCR assays for circulating tumor DNA monitoring in recurrent or metastatic head and neck cancer: a pilot study

In recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC), early identification of treatment response remains challenging because imaging may be delayed or confounded by treatment-related changes and atypical response patterns under immunotherapy. Serial circulating tumor DNA (ctDNA) analysis may...

Luca Leonardo Amodio, Lea Grossmann, Stefanie Gächter et al. · 0 citations
Oct 2026

Brief Report: Characterization of the Potentially Actionable TP53 Y220C Mutation in Non-Small Cell Lung Cancer. A Multicenter, European Thoracic Oncology Platform Study.

INTRODUCTION The tumor suppressor TP53 is the most frequently mutated gene in human cancer, and drugs targeting specific mutant p53 proteins have been developed. Rezatapopt, which reactivates the Y220C p53 protein, was recently evaluated in the Phase I PYNNACLE trial in patients with solid tumors, with promising result...

M. Molina-Vila, Z. Tsourti, A. Stenzinger et al. · 0 citations
Open access Sep 2026

Oncogene-driven genomic profiles are linked to poor overall survival in muscle-invasive bladder cancer (MIBC)

It is suggested that oncogene amplifications, rather than traditional genomic instability metrics, are associated with poor overall survival in MIBC, warranting validation in larger cohorts to assess their potential relevance as prognostic markers and therapeutic targets.

C. Poyet, A. S. Franzen, U. Bieri et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.